Publication

Article

Pharmacy Times

June 2018 Women's Health
Volume84
Issue 6

Generic Product News (June 2018)

Read about the generic products featured in June.

Aurobindo Pharma Ltd

COMPARE TO: Ortho Tri-Cyclen, Ortho Cyclen (Janssen)

INDICATION: Aurobindo Pharma has launched the Mili and Tri-Mili lines of oral-contraceptive tablets, an AB-rated generic equivalent to the reference listed drugs Ortho Cyclen and Ortho Tri-Cyclen. Mili is an estrogen/ progestin combined oral contracteptive (COC) indicated for use by women to prevent pregnancy. Tri-Mili is an estrogen/progestin COC indicated for use by women to prevent pregnancy. Tri-Mili is also indicated to treat moderate acne vulgaris in women at least 15 years of age who have no known contraindications to oral-contraceptive therapy and have achieved menarche.

DOSAGE FORM: Tablets

FOR MORE INFORMATION: AurobindoUSA.com

ERYTHROMYCINMARKETED BY: Amneal PharmaceuticalsCOMPARE TO: Erythromycin (Arbor Pharmaceuticals)

INDICATION: The FDA has approved Amneal’s erythromycin tablets, USP, 250- and 500-mg strengths as the therapeutic equivalent for the reference listed drug erythromycin tablets from Arbor. Erythromycin tablets are indicated to treat infections caused by susceptible strains of designated microorganisms.

DOSAGE FORM: Tablets: 250 and 500 mg

FOR MORE INFORMATION: amneal.com

EFAVIRENZ TABLETSMARKETED BY: Camber Pharmaceuticals

COMPARE TO: Sustiva (Bristol-Myers Squibb)

INDICATION: Camber Pharmaceuticals has launched efavirenz tablets, the generic version of Sustiva. Sustiva is indicated to treat HIV.

DOSAGE FORM: Tablets

FOR MORE INFORMATION: camberpharma.com

METHYLPHENIDATE CHEWABLE TABLETSMARKETED BY: Camber Pharmaceuticals

COMPARE TO: Methylin (Mallinckrodt)

INDICATION: Camber Pharmaceuticals has launched its methylphenidate chewable tablets, the generic version of Methylin. Methylin is indicated to treat attention-deficit/ hyperactivity disorder.

DOSAGE FORM: Tablets

FOR MORE INFORMATION: camberpharma.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs